Business
Podium Presentation and Publication for Data
Podium Presentation and Publication for Data.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n RNS Number : 2937H\n Renalytix AI PLC\n 24 March 2020\n \n \n \n \n \n \n \n Renalytix AI plc\n \n \n (\"RenalytixAI\", the \"Company\")\n \n \n \n \n \n Podium Presentation and Publication for Health Economics Data\n \n \n \n \n \n Presentation titled: Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression\n \n \n \n \n \n Oral presentation accepted for Late Breaking session of the National Kidney Foundation Spring Clinical Meeting\n \n \n \n \n \n Accompanying abstract accepted for publication in American Journal of Kidney Disease\n \n \n \n \n \n Renalytix AI plc \n (LSE\n : RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces\n \n \n that data from a study highlighting the health economic benefits associated with \n \n \n KidneyIntelX™\n \n \n testing in diabetic kidney disease populations (DKD) will be presented at the National Kidney Foundation Spring Clinical Meeting being held in the United States. An abstract summarizing key results will be published in the peer reviewed journal, the \n \n \n American Journal of Kidney Disease.\n \n \n \n \n \n \n \n \n \n National Kidney Foundation Spring Clinical Meeting (26 March 2020)\n \n \n Thomas Goss, PharmD, Senior Vice President, Boston Healthcare Associates, will deliver a presentation titled Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression during the Late Breaking Abstract session at the National Kidney Foundation's Spring Clinical Meeting. The presentation will highlight the significant cost savings associated with the implementation of KidneyIntelX™in large health care system patient populations in the United States. The presentation is based on a comprehensive economic model developed by Boston Healthcare Associates utilizing peer reviewed clinical data to estimate the costs associated with chronic kidney disease progression in the U.S. The presentation session will be held on Thursday, 26 March 2020 at 4:15 PM ET. A summary of the presentation results will be made available on the Company's website. \n \n \n \n \n \n \n Thomas Goss, Seni...